Neurocrine Biosciences, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +28.6%
EBITDA: +70.8%
EBIT: +57.9%
EPS: +121.5%
Free cash flow: +68.9%
Operating cash flow: +63.0%

Forward estimates

Revenue: +21.3%
EBITDA: +45.5%
EPS: +13.3%

Three-year CAGR

Revenue: +24.3%
EBITDA: +41.2%
EBIT: +35.5%
Net income: +45.8%
EPS: +44.0%
Free cash flow: +32.4%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.